REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

01 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

31 Aug 2022 15:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress

09 Aug 2022 15:02:00 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

28 Jul 2022 15:02:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

22 Jul 2022 15:02:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock

19 Jul 2022 21:41:52 By Nasdaq GlobeNewswire

Revolution Medicines Announces Commencement of Public Offering of Common Stock

19 Jul 2022 15:01:00 By Nasdaq GlobeNewswire

Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

13 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236

28 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference

09 Jun 2022 15:02:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress

09 May 2022 15:02:00 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022

21 Apr 2022 15:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022

09 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference

01 Mar 2022 15:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress

28 Feb 2022 15:05:01 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022

22 Feb 2022 15:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

03 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference

11 Jan 2022 13:15:00 By Nasdaq GlobeNewswire

Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference

24 Nov 2021 06:30:00 By Nasdaq GlobeNewswire